Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure
Author:
Funder
Eli Lilly and Company
Publisher
Springer Science and Business Media LLC
Subject
Dermatology
Link
https://link.springer.com/content/pdf/10.1007/s13555-022-00743-9.pdf
Reference34 articles.
1. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72. https://doi.org/10.1016/j.jaad.2018.11.057.
2. Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39–50. https://doi.org/10.2147/JIR.S100940.
3. Toussirot E. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2018;18(1):101–7. https://doi.org/10.1080/14712598.2018.1410133.
4. Paller AS, Seyger MM, Magariños G, Bagel J, Pinter A, Cather J, et al. Efficacy and safety of ixekizumab in a phase 3, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183:231–41.
5. Prescribing Information—Taltz. http://uspl.lilly.com/taltz/taltz.html#pi. Accessed 23 Apr 2020.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities;Dermatology and Therapy;2024-04
2. Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA;Modern Rheumatology Journal;2024-02-17
3. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials;Arthritis Research & Therapy;2024-02-12
4. Basophil activation test in diagnosis of immediate hypersensitivity reactions to IL‐17A inhibitors;Journal of the European Academy of Dermatology and Venereology;2023-11-27
5. Effective Anti-IL-17 response in psoriasis affecting hard-to-treat places with previous immunobiological failure;Journal of Dermatology & Cosmetology;2023-11-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3